Home LiteratureArticle Details
PMID: 9364483 Published · ppublish English Journal Article

Effects of divalent cations, protons and calmidazolium at the rat P2X7 receptor.

Neuropharmacology ·Vol. 36 ·No. 9 ·1997-09-00 ·Pages 1285-94

Virginio C, Church D, North RA, Surprenant A

Abstract

The P2X7 receptor is a uniquely bifunctional molecule through which ATP can open a small cationic channel typical of ionotropic receptors and also induce a large pore permeable to high molecular weight molecules (> 600 Da). Activation of this large pore can lead to cell lysis within 1-2 min. We asked whether pharmacological differences existed between the cationic channel and the cell permeabilizing pore by measuring whole-cell currents and uptake of a propidium dye (YO-PRO; Mw 629) in HEK293 cells stably expressing the rat P2X7 receptor, and comparing the actions of divalent cations and protons in these two assays. Currents in response to 2'-3'-(O)-(4-benzoyl benzoyl) ATP (BzATP, 30 microM) were inhibited by extracellular calcium, magnesium, zinc, copper and protons with half-maximal inhibitory concentrations (IC50) of 2.9 mM, 0.5 mM, 11 microM, 0.5 microM and 0.4 microM, respectively. The inhibition was voltage independent in each case. YO-PRO uptake induced by BzATP was also inhibited with similar IC50 values. The rank order of potency of a range of divalents was Cu2+ > Cd2+ = Zn2+ > Ni2+ >> Mg2+ = Co2+ > Mn2+ > Ca2+ = Ba2+ >> Sr2+. These results suggest that these divalent cations and protons all act primarily as allosteric modulators to alter the affinity of ATP binding to the P2X7 receptor. In contrast, extracellular (but not intracellular) calmidazolium inhibited the BzATP-evoked current by up to 90% (IC50 = 15 nM) but had no effect on YO-PRO uptake. Thus, calmidazolium can block activation of the ionic channel but this does not prevent the formation of the large permeabilizing pore.

MeSH Terms
Adenosine Triphosphate/analogs & derivatives,pharmacology Affinity Labels/pharmacology Animals Cations, Divalent/pharmacology Cell Line Enzyme Inhibitors/pharmacology Humans Imidazoles/pharmacology In Vitro Techniques Kidney Magnesium/pharmacology Patch-Clamp Techniques Protons Purinergic P2 Receptor Agonists Purinergic P2 Receptor Antagonists Rats Receptors, Purinergic P2/drug effects Receptors, Purinergic P2X7 Spectrometry, Fluorescence
Chemicals
Affinity Labels Cations, Divalent Enzyme Inhibitors Imidazoles P2RX7 protein, human P2rx7 protein, rat Protons Purinergic P2 Receptor Agonists Purinergic P2 Receptor Antagonists Receptors, Purinergic P2 Receptors, Purinergic P2X7 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate calmidazolium Adenosine Triphosphate Magnesium
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Virginio C
Geneva Biomedical Research Institute, Glaxo Wellcome, Switzerland. CV49987@ggr.co.uk
Church D
North R A
Surprenant A
Article Info
Journal
Neuropharmacology
Abbr.
Neuropharmacology
ISSN
0028-3908
Published
1997-09-00
Pages
1285-94
Language
English
Region
England
NLM ID
0236217
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com